Abivax S.A. (Nasdaq:ABVX)
Health Care/Life Sciences • Pharmaceuticals
CIK 1956827
Company
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.
Address
7-11 Boulevard Haussmann
Paris, Ile-de-France 75009
7-11 Boulevard Haussmann
Paris, Ile-de-France 75009
Employees
24
24
Stock Info
Key Executives
Board Of Directors
|
Chairman & Chief Executive Officer Marc M. P de Garidel EMBA |
|
Director Paolo Rampulla |
|
Director Kinam Hong MD, MBA |
|
Director Philippe Pouletty MD |
|
Director June H Lee MD |
|
Director Troy A Ignelzi |
|
Independent Director Carol L Brosgart MD |
|
Independent Director Corinna Zur Bonsen-Thomas |
SEC filings
| Date | Form | Event |
|---|---|---|
| 26 Nov, 2024 | EFFECT | |
| 19 Nov, 2024 | 6-K | |
| 19 Nov, 2024 | F-3 | |
| 14 Nov, 2024 | 6-K | |
| 14 Nov, 2024 | SC 13G/A | |
| 3 Oct, 2024 | 6-K | |
| 3 Oct, 2024 | 6-K | |
| 26 Sep, 2024 | 6-K | |
| 25 Sep, 2024 | 6-K | |
| 9 Sep, 2024 | 6-K | |
| 9 Sep, 2024 | 6-K | |
| 6 Aug, 2024 | 6-K | |
| 16 Jul, 2024 | 6-K | |
| 4 Jun, 2024 | 6-K | |
| 7 May, 2024 | 6-K | |
| 19 Apr, 2024 | SC 13G | |
| 5 Apr, 2024 | 20-F | |
| 2 Apr, 2024 | 6-K | |
| 14 Feb, 2024 | SC 13G/A | |
| 2 Feb, 2024 | 6-K | |
| 22 Jan, 2024 | 6-K | |
| 22 Nov, 2023 | SC 13G | |
| 30 Oct, 2023 | SC 13G | |
| 30 Oct, 2023 | SC 13D | |
| 23 Oct, 2023 | 424B4 | IPO completed |
| 20 Oct, 2023 | SEC STAFF | |
| 20 Oct, 2023 | FWP | |
| 19 Oct, 2023 | EFFECT | |
| 19 Oct, 2023 | CERT | |
| 19 Oct, 2023 | EFFECT | |
| 18 Oct, 2023 | F-1/A | |
| 18 Oct, 2023 | 8-A12B | |
| 18 Oct, 2023 | CORRESP | |
| 18 Oct, 2023 | CORRESP | |
| 18 Oct, 2023 | CORRESP | |
| 17 Oct, 2023 | UPLOAD | |
| 16 Oct, 2023 | CORRESP | |
| 16 Oct, 2023 | F-1/A | |
| 5 Oct, 2023 | UPLOAD | |
| 3 Oct, 2023 | F-6 | |
| 29 Sep, 2023 | F-1 | |
| 29 Sep, 2023 | CORRESP | |
| 20 Sep, 2023 | SEC STAFF | |
| 20 Sep, 2023 | UPLOAD | |
| 8 Sep, 2023 | DRSLTR | |
| 8 Sep, 2023 | DRS/A | |
| 18 Aug, 2023 | UPLOAD | |
| 28 Jul, 2023 | DRS/A | |
| 28 Jul, 2023 | DRSLTR | |
| 12 Jan, 2023 | UPLOAD | |
| 16 Dec, 2022 | DRS |
Last update:2024-03-06 12:13:34.321059
Sign Up to Subscribe
Interested in special situations?
Join Tickerverse
- customize event filters
- create watchlists, bookmarks
- get email notifications for the latest special situations
- browse and analyze public companies, executives and SEC filings
Tickerverse is a great way to find investment opportunities in corporate actions.
By signing up you agree to our Terms of Service and Privacy Policy.